Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2024-05-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thalidomide in Pediatric Inflammatory Bowel Diseases.
NCT00720538
Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients
NCT02998827
Thalidomide in Treating Crohn's Disease
NCT02501291
Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
NCT02956538
Epidemiological Screening of IL10RA Mutation Rate in China
NCT03097731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thalidomide
thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* disease onset less than 6 years old
* Pediatric Crohn's disease Activity Index (PCDAI)\>30 or Pediatric Ulcerative Colitis Activity Index (PUCAI)\>35
* patients and their legal guardians were willing to receive thalidomide treatment and participate in this study.
Exclusion Criteria
* allergy to thalidomide
* with Neuropathy
* with thrombosis
* thalidomide treatment in the previous 30 days
* biologics treatment in the previous 8 weeks
* not suitable participated in this study
28 Days
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital of Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying HUANG
Head of gastroenterology department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying Huang
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital of Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lin Wang
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Thal in VEOIBD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.